Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
| ▸ | FAAH | O00519 | 5/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5715189 | 0.95 | TP53 (0.43) | TP53LMNAKEAP1NFE2L2RXFP1 | |
| SCHEMBL5714472 | 0.93 | SIGMAR1 (0.42) | ADORA3HTR2AHTR7OPRM1SIGMAR1 | |
| SCHEMBL5714958 | 0.92 | SIGMAR1 (0.44) | ADORA3HTR2AHTR7OPRM1SIGMAR1 | |
| SCHEMBL5715131 | 0.91 | FAAH (0.41) | ADORA3HTR2AHTR7OPRM1SIGMAR1 | |
| SCHEMBL5715388 | 0.90 | TP53 (0.48) | ADORA3HTR2AHTR7OPRM1SIGMAR1 | |
| SCHEMBL5714875 | 0.89 | TP53 (0.47) | ADORA3HTR2AHTR7OPRM1SIGMAR1 | |
| SCHEMBL5714814 | 0.89 | TP53 (0.47) | ADORA3HTR2AHTR7OPRM1SIGMAR1 | |
| SCHEMBL5715379 | 0.87 | AOC3 (0.42) | ADORA3HTR2AHTR7OPRM1SIGMAR1 | |
| SCHEMBL5714786 | 0.87 | SIGMAR1 (0.47) | ADORA3HTR2AHTR7OPRM1SIGMAR1 | |
| SCHEMBL5715177 | 0.86 | SIGMAR1 (0.44) | ADORA3HTR2AHTR7OPRM1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006527212-A | — | — | 2006-11-30 | — | — | JP | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | ADORA3 3862/4885HTR2A 1618/4885HTR7 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.